Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
CCL2 for the Treatment of Inflammation
Yeda R&D Co. Ltd Israel flag Israel
Abstract ID:
A method to treat inflammatory disorders.Malfunctions of the immune system are responsible for a series of inflammatory disorders. Two such disorders are rheumatoid arthritis and asthma, encompassing together approximately 23 million Americans. No......
Contact Galit Mazooz, ph.d.
Participants
You
Email me a copy of this message

A method to treat inflammatory disorders.


Malfunctions of the immune system are responsible for a series of inflammatory disorders. Two such disorders are rheumatoid arthritis and asthma, encompassing together approximately 23 million Americans. No definitive treatment is currently available for these diseases, and therefore they remain chronic diseases which require life long treatment, accompanied with inconvenient use of drugs together with unwanted side effects. The present invention offers a method to treat inflammation by a molecule that down-regulates the movement of immune cells.



Applications




    • Treatment of inflammation associated with allergy and autoimmune diseases





Advantages




    • Treatment of a wide variety of diseases using a single molecule (CCL2)





    • No associated side-effects 





Technology's Essence


CCL2 is well known to specifically attract T cells. This molecule was found to be involved in various inflammatory responses. In the current technology it is suggested that administration of low levels of CCL2 (rather than its inhibition) may be used to effectively reduce T cell migration and homing into lymph nodes, and as such may be clinically beneficial as an anti-inflammatory agent in inflammatory diseases.



Licensing Status

GO PREMIUM TO GET PATENT INFORMATION
FEATURED
Last Updated May 2016
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE
CORPORATION